NI201600134A - Compuestos químicos - Google Patents

Compuestos químicos

Info

Publication number
NI201600134A
NI201600134A NI201600134A NI201600134A NI201600134A NI 201600134 A NI201600134 A NI 201600134A NI 201600134 A NI201600134 A NI 201600134A NI 201600134 A NI201600134 A NI 201600134A NI 201600134 A NI201600134 A NI 201600134A
Authority
NI
Nicaragua
Prior art keywords
chemical compounds
compound
enac
copd
asthma
Prior art date
Application number
NI201600134A
Other languages
English (en)
Inventor
Elisabeth Berglund Susanne
Hossain Nafizal
Nikitidis Grigorios
Elisabeth Ripa Lena
Shamovsky Igor
Hemmerling Martin
Connolly Stephen
Kristoffersson Anna
Rune Michael Lundkvist Johan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201600134A publication Critical patent/NI201600134A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de una fórmula (I): o una sal farmacéuticamente aceptable de este; un proceso para preparar tal compuesto; y el uso de tal compuesto en el tratamiento de un estado de enfermedad mediado por ENaC (tal como asma, CF o COPD).
NI201600134A 2014-03-18 2016-09-13 Compuestos químicos NI201600134A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461954674P 2014-03-18 2014-03-18

Publications (1)

Publication Number Publication Date
NI201600134A true NI201600134A (es) 2017-03-13

Family

ID=52780553

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201600134A NI201600134A (es) 2014-03-18 2016-09-13 Compuestos químicos

Country Status (38)

Country Link
US (3) US9873678B2 (es)
EP (1) EP3119752B1 (es)
JP (1) JP6502469B2 (es)
KR (1) KR102296041B1 (es)
CN (1) CN106103423B (es)
AP (1) AP2016009447A0 (es)
AR (1) AR099790A1 (es)
AU (1) AU2015233195B2 (es)
CA (1) CA2941807C (es)
CL (1) CL2016002303A1 (es)
CR (1) CR20160479A (es)
CY (1) CY1120509T1 (es)
DK (1) DK3119752T3 (es)
DO (1) DOP2016000232A (es)
EA (1) EA029952B1 (es)
ES (1) ES2679618T3 (es)
GT (1) GT201600190A (es)
HR (1) HRP20181123T1 (es)
HU (1) HUE039425T2 (es)
IL (1) IL247610B (es)
LT (1) LT3119752T (es)
ME (1) ME03056B (es)
MX (1) MX368577B (es)
NI (1) NI201600134A (es)
NZ (1) NZ724063A (es)
PE (1) PE20170205A1 (es)
PH (1) PH12016501808B1 (es)
PL (1) PL3119752T3 (es)
PT (1) PT3119752T (es)
RS (1) RS57487B1 (es)
SG (1) SG11201607751SA (es)
SI (1) SI3119752T1 (es)
SV (1) SV2016005278A (es)
TR (1) TR201810207T4 (es)
TW (1) TWI687410B (es)
UY (1) UY36034A (es)
WO (1) WO2015140527A1 (es)
ZA (1) ZA201607136B (es)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577418A (en) 1969-02-12 1971-05-04 Merck & Co Inc Pyrazinamide derivatives and processes for their preparation
US3573306A (en) 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
FI820266L (fi) 1981-02-02 1982-08-03 Ici Plc Alkanolaminderivater
DE3361244D1 (de) 1982-01-29 1986-01-02 Ici Plc Alkanolamine derivatives
GB8810934D0 (en) 1987-05-26 1988-06-15 Ici America Inc Amides
GB8810933D0 (en) 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
US4803206A (en) 1988-03-07 1989-02-07 Schering Corporation Antihypertensive acylpyrazines
GB8812343D0 (en) 1988-05-25 1988-06-29 Ici America Inc Amino compounds
GB8812342D0 (en) 1988-05-25 1988-06-29 Ici America Inc Bicyclic compounds
EP0966443B1 (en) 1997-02-26 2009-01-28 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
GB9930557D0 (en) 1999-12-23 2000-02-16 Rolic Ag Optically active materials
CA2876779A1 (en) 2000-05-12 2001-11-22 Genzyme Corporation Modulators of tnf-.alpha. signaling
OA12846A (en) 2001-11-08 2006-09-15 Elan Pharm Inc N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives.
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040087571A1 (en) 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
JP2006516028A (ja) 2002-12-20 2006-06-15 ファイザー・プロダクツ・インク ミクロソームトリグリセリド輸送タンパク質阻害剤
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
AU2005295878A1 (en) 2004-10-13 2006-04-27 University Of Connecticut Cannabinergic lipid ligands
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8822497B2 (en) 2007-03-01 2014-09-02 Novartis Ag PIM kinase inhibitors and methods of their use
CA2685546A1 (en) 2007-05-07 2008-11-13 Novartis Ag Organic compounds
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2009248179A1 (en) 2008-05-13 2009-11-19 Novartis Ag 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
MX2010013675A (es) 2008-06-10 2011-02-15 Novartis Ag Derivados de pirazina como bloqueadores del canal de sodio epitelial.
WO2011028740A1 (en) * 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US9505735B2 (en) 2012-06-21 2016-11-29 Whitehead Institute For Biomedical Research Compounds for treating infectious diseases
AP2015008556A0 (en) 2012-12-17 2015-06-30 Parion Sciences Inc Chloro-pyrazine carboxamide derivatives useful forthe treatment of diseases favoured by insufficien t mucosal hydration
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
AU2013363215B2 (en) 2012-12-17 2018-03-01 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds

Also Published As

Publication number Publication date
US20170107195A1 (en) 2017-04-20
IL247610B (en) 2019-05-30
SG11201607751SA (en) 2016-10-28
CA2941807C (en) 2023-03-07
HUE039425T2 (hu) 2018-12-28
TWI687410B (zh) 2020-03-11
MX2016011681A (es) 2016-10-28
AP2016009447A0 (en) 2016-09-30
ES2679618T3 (es) 2018-08-29
CL2016002303A1 (es) 2017-01-13
CN106103423B (zh) 2019-12-06
JP2017512830A (ja) 2017-05-25
UY36034A (es) 2015-09-30
ZA201607136B (en) 2018-04-25
PE20170205A1 (es) 2017-04-06
PT3119752T (pt) 2018-07-24
AR099790A1 (es) 2016-08-17
JP6502469B2 (ja) 2019-04-17
US9873678B2 (en) 2018-01-23
PH12016501808A1 (en) 2017-01-09
PH12016501808B1 (en) 2017-01-09
CA2941807A1 (en) 2015-09-24
SV2016005278A (es) 2016-11-30
CR20160479A (es) 2017-02-24
US10954211B2 (en) 2021-03-23
AU2015233195A1 (en) 2016-09-22
EA201691641A1 (ru) 2017-02-28
CY1120509T1 (el) 2019-07-10
KR102296041B1 (ko) 2021-08-30
WO2015140527A1 (en) 2015-09-24
GT201600190A (es) 2019-07-29
EA029952B1 (ru) 2018-06-29
HRP20181123T1 (hr) 2018-09-21
SI3119752T1 (en) 2018-08-31
TR201810207T4 (tr) 2018-08-27
EP3119752A1 (en) 2017-01-25
CN106103423A (zh) 2016-11-09
MX368577B (es) 2019-10-08
US10336725B2 (en) 2019-07-02
DOP2016000232A (es) 2016-10-16
NZ724063A (en) 2018-02-23
LT3119752T (lt) 2018-08-10
KR20160127135A (ko) 2016-11-02
US20190330187A1 (en) 2019-10-31
ME03056B (me) 2018-10-20
RS57487B1 (sr) 2018-10-31
PL3119752T3 (pl) 2018-09-28
DK3119752T3 (en) 2018-07-30
AU2015233195B2 (en) 2017-04-20
IL247610A0 (en) 2016-11-30
TW201620880A (zh) 2016-06-16
EP3119752B1 (en) 2018-05-16
US20180162838A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
CL2016001963A1 (es) Heteroarilos inhibidores de syk
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
GEP20186921B (en) Pyrazolopyridines and pyrazolopyrimidines
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CL2015001442A1 (es) Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2013002007A1 (es) Compuesto polimorfo (s)-3-(1-(9h-purin-6-ilamino)etil)-8-cloro-2-fenilisoquinolin-1-(2h)-ona de formas b-j, amorfa, sal, solvato o hidrato del mismo; mezclas de estos compuestos; metodo para preparar el polimorfo de forma c; composicion farmaceutica; metodo de tratamiento; uso para el tratamiento de un trastorno mediado por pi3k.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR103680A1 (es) Inhibidores selectivos de bace1
EA201791304A1 (ru) Производные изохинолина для лечения вич
TW201613864A (en) Novel compounds
NI201800071A (es) Compuestos de isoindol
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
AR100289A1 (es) Formas de un inhibidor de pi3k
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
BR112017003651A2 (pt) derivados de isoquinolinona úteis no tratamento de câncer